Pharmaceuticals
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial
This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib(ABSK021)was granted BTD by FDA and CDE, discovered and developed byChina biotech。 SHANGHAI, March 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as "Abbis...
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of anti...
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
MELBOURNE, Australia, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga...
Akeso Reported 2022 Annual Results
* Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaledRMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded strong sales ofRMB546.3 million in its first six months of approval in China. 安尼可®(penpulimab injection, PD-1) recorded product sales ofRMB...
Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD
* Ark Biopharmaceutical will lead development activities for AK0705 with the goal of initiating clinical studies in 2024. * Calibr will continue to collaborate in the development of AK0705. * The collaboration is an extension of the current co-development collaboration. SHANGHAI, March 16, 2...
Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting
* The abstract of BBT-207 preclinical studies is now available on the AACR
website
Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
SHANGHAI, March 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the full year endedDecember 31, 20...
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, ...
Nippon Express (Belgium) Joins Pharma.Aero
TOKYO, March 15, 2023 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a group company of NIPPON EXPRESS HOLDINGS, INC., became the first Japanese forwarder to join Pharma.Aero (*) onJanuary 25 this year. Pharma.Aero logo: https://kyodonewsprwire.jp/img/202303033576...
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
BEIJING and SHANGHAI and BOSTON, Mass., March 14, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the...
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023
SUZHOU, China, March 15, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) is accepted as Late-Breaking Research in 114th Annual Meeting of the American Association for Cancer Research (AACR 2023). The res...
Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting
SUZHOU, China and ROCKVILLE, Md., March 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest results from three preclinical s...
YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION
* Business Combination to deliver approximately $36 million of gross proceeds * YS Biopharma expects to close the Business Combination on March 16, 2023 * YS Biopharma Ordinary Shares and YS Biopharma Warrants expected to begin trading on the Nasdaq onMarch 17, 2023 under the symbols "YS" and...
Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011
SHANGHAI, March 14, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011. The study (CTR20230046) is a phase 1, single cente...
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
New Business Strategy Focused on Precision Oncology LONDON and HONG KONG, March 14, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full yea...
Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)
* Clinically meaningful achievement of primary and secondary endpoints is first major advance in treatment of low-grade glioma in more than 20 years * Endpoints met in a prespecified interim analysis * vorasidenib granted fast track designation by U.S. Food & Drug Administration (FDA) PARI...
Ajinomoto Bio-Pharma Services Awarded Three 'CDMO Leadership Awards'
SAN DIEGO and TOKYO and WETTEREN, Belgium, March 14, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received three CDMO Leadership Awards in the categories Capabilities, Compatibility,...
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma
NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreeme...
Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer
HONG KONG, March 14, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), the world's first approved and marketed dual-immune checkpoint bi-specific antib...
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China
- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. - The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in pat...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24